Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
20
Not yet recruiting, industry sponsors, Neurology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting104
- Completed1,034
20 trials
Showing 1 to 20, recently updated first.
- A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)Pivotal-lookingNot yet recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07937852 · 1,800 participants (planned) · Start Jan 18, 2027 · Primary completion Nov 30, 2029
Drug: Fenebrutinib · For: Multiple Sclerosis
- Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in AdultsPivotal-lookingNot yet recruiting
Brise Pharmaceuticals Co., Ltd.Industry
NCT07835152 · 1,000 participants (planned) · Start Nov 20, 2026 · Primary completion Mar 31, 2029
Drug: BR005-036C · For: Migraine, With or Without Aura
Sites: Shanxi, China; Inner Mongolia, China; Beijing, China · 79 sites in all
- An Open-label Long-term Safety Study of Buntanetap in Participants With ADPivotal-lookingNot yet recruiting
Annovis Bio Inc.Industry
NCT07757204 · 400 participants (planned) · Start Nov 21, 2026 · Primary completion Feb 21, 2030
Drug: buntanetap/posiphen · For: Alzheimer's Dementia (AD)
Sites: Englewood, Colorado; Daytona Beach, Florida; Maitland, Florida · 14 sites in all
- A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisPivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07930624 · 2,500 participants (planned) · Start Feb 15, 2027 · Primary completion May 16, 2031
Drug: Frexalimab; Frexalimab and 6 more · For: Multiple Sclerosis
- Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years OldPivotal-lookingNot yet recruiting
Immedica Pharma ABIndustry
NCT05249556 · 12 participants (planned) · Start Mar 2027 · Primary completion Dec 2029
Drug: Ganaxolone · For: CDKL5 Deficiency Disorder
- Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) StudyPivotal-lookingNot yet recruiting
CerecinIndustry
NCT05809908 · 535 participants (planned) · Start Jul 2027 · Primary completion Jan 2030
Drug: Tricaprilin; Placebo · For: Alzheimer Disease
- A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)Pivotal-lookingNot yet recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07825402 · 486 participants (planned) · Start Jan 2027 · Primary completion Oct 2029
Drug: ONO-2808 · For: Multiple System Atrophy, Parkinson Variant
- Efficacy and Safety of Tazbentetol in ALS ParticipantsPivotal-lookingNot yet recruiting
SpinogenixIndustry
NCT07325591 · 430 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2027
Drug: Tazbentetol; placebo · For: Amyotrophic Lateral Sclerosis
- Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2Pivotal-lookingNot yet recruiting
Semnur Pharmaceuticals, Inc.Industry
NCT07579351 · 755 participants (planned) · Start Feb 2027 · Primary completion Nov 2028
Drug: SP-102; Placebo and 1 more · For: Lumbosacral Radicular Pain
- To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Pivotal-lookingNot yet recruiting
Eidos Therapeutics, a BridgeBio companyIndustry
NCT07116473 · 250 participants (planned) · Start Nov 2026 · Primary completion Nov 2037
Drug: Acoramidis (AG10) · For: Amyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy and 7 more
- Alzheimer's Disease THErapy With NEuroaid IIPivotal-lookingNot yet recruiting
Moleac Pte Ltd.Industry
NCT07191028 · 350 participants (planned) · Start Aug 2026 · Primary completion Feb 2029
Drug: MLC 901; Placebo · For: Alzheimer's Disease Dementia
Sites: Singapore, Singapore
- GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)Pivotal-lookingNot yet recruiting
Samsung Pharmaceutical Co., Ltd.Industry
NCT05303701 · 750 participants (planned) · Start Jul 2027 · Primary completion Jan 2028
Drug: GV1001 Placebo; GV1001 1.12mg · For: Moderate to Severe Alzheimer's Disease
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Pivotal-lookingNot yet recruiting
BiogenBiogen (BIIB)
NCT07483632 · 185 participants (planned) · Start Nov 16, 2026 · Primary completion Jul 28, 2034
Drug: Diroximel Fumarate; Dimethyl Fumarate and 4 more · For: Relapsing Forms of Multiple Sclerosis
Gipfel Life Sciences GmbHIndustry
NCT07321860 · 60 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2027
Drug: Galunisertib + Nerandomilast Combination · For: ALS (Amyotrophic Lateral Sclerosis)
- A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple SclerosisPivotal-lookingNot yet recruiting
RVL Pharmaceuticals, Inc.Industry
NCT05179577 · 442 participants (planned) · Start Jan 2027 · Primary completion Jan 2028
Drug: Arbaclofen; Placebo · For: Spasticity
- Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic WoundsPivotal-lookingNot yet recruiting
Bardia AnvarIndustry
NCT07223892 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 2028
Drug: Amniotic Tissue Allograft · For: Chronic Wounds; Venous Leg Ulcers (VLUs); Diabetic Foot Ulcers (DFUs) and 5 more
- Masitinib in Patients With Mild Alzheimer's DiseasePivotal-lookingNot yet recruiting
AB ScienceIndustry
NCT05564169 · 600 participants (planned) · Start Jun 2026 · Primary completion Dec 2028
Drug: Placebo; Masitinib (4.5) and 1 more · For: Alzheimer Disease
Sites: Paris, France; Albacete, Spain; Barcelona, Spain · 9 sites in all
- Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS PatientsPivotal-lookingNot yet recruiting
AB ScienceIndustry
NCT07174492 · 412 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2028
Drug: Masitinib 4.5 mg/kg/day; Placebo and 1 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Athens, Greece
- Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)Pivotal-lookingNot yet recruiting
Brainstorm-Cell TherapeuticsIndustry
NCT06973629 · 200 participants (planned) · Start Jun 30, 2025 · Primary completion Nov 1, 2028
Drug: Debamestrocel - MSC-NTF (NurOwn); Placebo · For: Amyotrophic Lateral Sclerosis (ALS); Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 15 sites in all
- A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease SubjectsPivotal-lookingNot yet recruiting
T3D Therapeutics, Inc.Industry
NCT06964230 · 376 participants (planned) · Start Oct 26, 2026 · Primary completion Apr 2031
Drug: T3D-959 · For: Alzheimer's Disease
Sites: Durham, North Carolina
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.